Logo     Print Page  Close Window


SEC Filings


S-3
FIBROCELL SCIENCE, INC. filed this Form S-3 on 01/18/2019
Entire Document
 


SELECTED FINANCIAL DATA

You should read the following selected financial data together with our financial statements and the related notes contained in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in Item 1 of Part I of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2018, which are incorporated by reference into this prospectus, except that share and per share information for the periods ended December 31, 2017 and December 31, 2016 have been revised to reflect the 1-for-5 reverse stock split of our issued and outstanding shares of common stock effective at the close of business on May 24, 2018.

We have derived the statements of operations data for each of the two years ended December 31, 2017 and December 31, 2016 from the audited financial statements contained in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. We have derived the statements of operation data for the three months ended March 31, 2018 and March 31, 2017 from our unaudited historical condensed financial statements and related notes thereto contained in Item 1 of Part I of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2018. All per share information for the periods ended December 31, 2017 and December 31, 2016, and periods ended March 31, 2018 and March 31, 2017, have been revised to reflect the 1-for-5 reverse stock split of our issued and outstanding shares of common stock effective at the close of business on May 24, 2018.

The historical financial information set forth below may not be indicative of our future performance and should be read together with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our historical financial statements and notes to those statements included in Item 7 of Part II and Item 8 of Part II, respectively, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and any amendment or update thereto reflected in subsequent filings with the SEC, and all other annual, quarterly and other reports that we file with the SEC after the date of the initial registration statement of which this prospectus forms a part and that also are incorporated herein by reference.

Fibrocell Science, Inc.
Statement of Operations Summary
($ in thousands except share and per share data)
 
(Revised for Stock Split) Three Months Ended March 31, (Unaudited)
 
(Revised for Stock Split) Year Ended December 31,
 
2018
 
2017
 
2017
 
2016
Total revenue
$

 
$

 
$

 
$
355

Total cost of revenue
 
 
 
 
 
 
697
 
Gross loss
 
 
 
 
 
 
(342
)
 
 
 
 
 
 
 
 
Operating expenses
2,981
 
 
4,454
 
 
18,981
 
 
26,137
 
Operating loss
(2,981
)
 
(4,454
)
 
(18,981
)
 
(26,479
)
 
 
 
 
 
 
 
 
Other income (expense)
80
 
 
(553
)
 
2,741
 
 
11,187
 
Loss before income taxes
(2,901
)
 
(5,007
)
 
(16,240
)
 
(15,292
)
 
 
 
 
 
 
 
 
Income taxes
 
 
 
 
 
 
 
Net loss
(2,901
)
 
(5,007
)
 
(16,240
)
 
(15,292
)
 
 
 
 
 
 
 
 
Per Share Information:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss:
 
 
 
 
 
 
 
Basic*
$
(0.55
)
 
$
(2.98
)
 
$
(6.66
)
 
$
(5.22
)
Diluted
$
(0.55
)
 
$
(2.98
)
 
$
(6.67
)
 
$
(5.89
)
 
 
 
 
 
 
 
 
Weighted average number of common shares outstanding:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
5,672,976
 
 
2,940,625
 
 
3,092,543
 
 
2,928,364
 
Diluted
5,672,976
 
 
2,941,145
 
 
3,093,727
 
 
2,929,566
 

*Basic and Diluted net loss for the three months ended March 31, 2018 includes $203, and for the three months ended March 31, 2017 includes $3,754 in dividends paid in kind and deemed dividends to preferred stockholders. Basic and Diluted net loss for the year ended December 31, 2017 includes $4,363 in dividends paid in kind and deemed dividends to preferred stockholders.

9